Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Total Debt (2017 - 2025)

Bioceres Crop Solutions' Total Debt history spans 7 years, with the latest figure at $119.7 million for Q2 2025.

  • For Q2 2025, Total Debt fell 33.06% year-over-year to $119.7 million; the TTM value through Jun 2025 reached $119.7 million, down 33.06%, while the annual FY2025 figure was $119.7 million, 33.06% down from the prior year.
  • Total Debt for Q2 2025 was $119.7 million at Bioceres Crop Solutions, down from $178.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $178.9 million in Q2 2024 and bottomed at $25.9 million in Q4 2021.
  • The 5-year median for Total Debt is $92.2 million (2021), against an average of $97.2 million.
  • The largest annual shift saw Total Debt skyrocketed 66.16% in 2024 before it tumbled 33.06% in 2025.
  • A 5-year view of Total Debt shows it stood at $25.9 million in 2021, then skyrocketed by 186.3% to $74.2 million in 2022, then skyrocketed by 45.11% to $107.6 million in 2023, then skyrocketed by 66.16% to $178.9 million in 2024, then tumbled by 33.06% to $119.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIOX's Total Debt are $119.7 million (Q2 2025), $178.9 million (Q2 2024), and $107.6 million (Q2 2023).